Management of Resistant Hypertension
Initial Treatment Approach
- The American Heart Association recommends a three-drug regimen consisting of a renin-angiotensin system (RAS) blocker, a calcium channel blocker (CCB), and a diuretic at maximally tolerated doses for patients with resistant hypertension 1
- Substitute chlorthalidone 12.5-25mg daily or indapamide 1.25-2.5mg daily for HCTZ, as these thiazide-like diuretics are preferred due to their longer duration of action and superior outcomes data compared to HCTZ 1, 2
- Chlorthalidone maintains efficacy down to estimated glomerular filtration rates (eGFR) of 30 mL/min/1.73m² 1
Fourth-Line Agent for Resistant Hypertension
- Add spironolactone 25-50mg daily as the preferred fourth-line agent for resistant hypertension, which has demonstrated additional blood pressure reductions in this setting 1, 2, 3
- Monitor potassium closely when adding spironolactone to lisinopril, as hyperkalemia risk is significant with dual RAS blockade and potassium-sparing diuretics 1, 2
Fifth and Sixth-Line Options
- Add hydralazine 25mg three times daily, titrating upward to maximum dose as the fifth-line agent 1
- Substitute minoxidil 2.5mg two to three times daily for hydralazine as a sixth-line option, though this requires concomitant use of a beta-blocker and loop diuretic to prevent reflex tachycardia and fluid retention 1
Critical Steps Before Adding Medications
- Confirm true treatment resistance by performing 24-hour ambulatory blood pressure monitoring (or home blood pressure monitoring if unavailable) to exclude white-coat effect and verify medication adherence 1
- Ensure sodium restriction to <2400mg/day (ideally <2000mg/day), as inadequate dietary sodium restriction is a common cause of apparent treatment resistance 1, 2
- Screen for secondary causes of hypertension, including primary aldosteronism, renal artery stenosis, obstructive sleep apnea, and thyroid disorders, particularly if blood pressure remains >160/100 mmHg despite three agents 1
Monitoring Parameters
- Check serum potassium and creatinine 2-4 weeks after initiating any diuretic therapy to detect hypokalemia (with thiazides/loops) or hyperkalemia (with spironolactone) 2, 3
- Reassess blood pressure within 2-4 weeks after medication adjustments, with the goal of achieving target blood pressure (<130/80 mmHg for most patients) within 3 months 2, 3
Common Pitfalls to Avoid
- Do not add a second beta-blocker or increase metoprolol dose as the next step—this violates guideline-recommended stepwise approaches and does not address the missing diuretic component of triple therapy 1, 2
- Do not combine lisinopril with an ARB (angiotensin receptor blocker), as dual RAS blockade increases adverse events without additional benefit 2
- Do not delay treatment intensification in patients with stage 2 hypertension (≥140/90 mmHg), as prompt action reduces cardiovascular risk 2